Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation

Sponsor

Peking University Third Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05638841

Collaborator

(none)

500

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

In this study, the continuous inclusion of atrial fibrillation patients treated by catheter ablation in the Department of Cardiology, Peking University Third Hospital, through the collection of clinical data and outpatient follow-up, to explore the risk factors of atrial fibrillation recurrence after catheter ablation and the influencing factors of major clinical events in atrial fibrillation patients, and further guide the management mode of atrial fibrillation patients.

Condition or Disease	Intervention/Treatment	Phase
Atrial Fibrillation	Other: After radiofrequency ablation of atrial fibrillation

Study Design

Study Type:

Observational

Anticipated Enrollment :

500 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation

Anticipated Study Start Date :

Dec 1, 2022

Anticipated Primary Completion Date :

Dec 31, 2023

Anticipated Study Completion Date :

Dec 31, 2025

Arms and Interventions

Arm	Intervention/Treatment
atrial fibrillation After radiofrequency ablation of patients with atrial fibrillation	Other: After radiofrequency ablation of atrial fibrillation This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.

Arm

Intervention/Treatment

atrial fibrillation

After radiofrequency ablation of patients with atrial fibrillation

Other: After radiofrequency ablation of atrial fibrillation

This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.

Outcome Measures

Primary Outcome Measures

Compound cardiovascular event [24 months]
Stroke, hemorrhage, re-hospitalization for atrial fibrillation and heart failure, and all-cause death

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

1. Age > 18
1. ECG or holter electrocardiogram confirmed atrial fibrillation

Exclusion Criteria:

1. Hematological diseases, autoimmune diseases and malignant tumors
1. Immobility caused by hemiplegia or severe trauma
1. The expected survival time is less than 2 years
1. Stage 4 or 5 chronic renal insufficiency (eGFR<30)
1. Poor compliance and high risk of expected loss of follow-up
1. Disorders of consciousness or Alzheimer's disease

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Peking University Third Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Peking University Third Hospital

ClinicalTrials.gov Identifier:

NCT05638841

Other Study ID Numbers:

2022-653-01

First Posted:

Dec 6, 2022

Last Update Posted:

Dec 6, 2022

Last Verified:

Nov 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Atrial Fibrillation

Study Results

No Results Posted as of Dec 6, 2022